Zyxin is a novel target for beta-amyloid peptide: Characterization of its role in Alzheimer's pathogenesis

Journal of Neurochemistry

Volumn 125, Issue 5, 2013, Pages 790-799

  Lanni, Cristina ^a   Necchi, Daniela ^a   Pinto, Antonella ^a   Buoso, Erica ^a   Buizza, Laura ^b   Memo, Maurizio ^b   Uberti, Daniela ^b   Govoni, Stefano ^a   Racchi, Marco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Alzheimer's disease; beta amyloid peptides; conformationally altered p53; metallothionein 2A; zyxin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; METALLOTHIONEIN II; PROTEIN P53; RETINOIC ACID; ZYXIN;

ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HEK293; CELL STRAIN SH SY5Y; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; ENZYME STABILITY; HUMAN; HUMAN CELL; IMMUNODETECTION; MOLECULAR MECHANICS; NEUROBLASTOMA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HUMANS; PEPTIDE FRAGMENTS; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; ZYXIN;

EID: 84878016988     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12154     Document Type: Article

References (40)

1. Alves da Costa C., and, Checler F., (2011) Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell. Signal. 23, 963-968.
2. Barten D. M., and, Albright C. F., (2008) Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol. 37, 171-186.
3. Beckerle M. C., (1997) Zyxin: zinc fingers at sites of cell adhesion. BioEssays 19, 949-957.
4. Bitan G., Kirkitadze M. D., Lomakin A., Vollers S. S., Benedek G. B., and, Teplow D. B., (2003) Amyloid beta -protein (Abeta) assembly: abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl Acad. Sci. USA 100, 330-335.
5. Copani A., Caraci F., Hoozemans J. J., Calafiore M., Sortino M. A., and, Nicoletti F., (2007) The nature of the cell cycle in neurons: focus on a "non-canonical" pathway of DNA replication causally related to death. Biochim. Biophys. Acta 1772, 409-412.
6. Copani A., Guccione S., Giurato L., Caraci F., Calafiore M., Sortino M. A., and, Nicoletti F., (2008) The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development. Curr. Med. Chem. 15, 2420-2432.
7. Crone J., Glas C., Schultheiss K., Moehlenbrink J., Krieghoff-Henning E., and, Hofmann T. G., (2011) Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis. Cancer Res. 71, 2350-2359.
8. Degenhardt Y. Y., and, Silverstein S., (2001) Interaction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocation. J. Virol. 75, 11791-11802.
9. Fujita Y., Yamaguchi A., Hata K., Endo M., Yamaguchi N., and, Yamashita T., (2009) Zyxin is a novel interacting partner for SIRT1. BMC Cell Biol. 10, 6.
10. Hervy M., Hoffman L. M., Jensen C. C., Smith M., and, Beckerle M. C., (2010) The LIM protein zyxin binds CARP-1 and promotes apoptosis. Genes Cancer 1, 506-515.
11. Joerger A. C., and, Fersht A. R., (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 2226-2242.
12. Jope R. S., Yuskaitis C. J., and, Beurel E., (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32, 577-595.
13. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and, Malinow R., (2003) APP processing and synaptic function. Neuron 37, 925-937.
14. Kato T., Muraski J., Chen Y., Tsujita Y., Wall J., Glembotski C. C., Schaefer E., Beckerle M., and, Sussman M. A., (2005) Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J. Clin. Invest. 115, 2716-2730.
15. Knauer M. F., Soreghan B., Burdick D., Kosmoski J., and, Glabe C. G., (1992) Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc. Natl Acad. Sci. USA 89, 7437-7441.
16. Lanni C., Mazzucchelli M., Porrello E., Govoni S., and, Racchi M., (2004) Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. Eur. J. Biochem. 271, 3068-3075.
17. Lanni C., Uberti D., Racchi M., Govoni S., and, Memo M., (2007) Unfolded p53: a potential biomarker for Alzheimer's disease. J. Alzheimers Dis. 12, 93-99.
18. Lanni C., Racchi M., Mazzini G., et al,. (2008) Conformationally altered p53: a novel Alzheimer's disease marker?. Mol. Psychiatry 13, 641-647.
19. Lanni C., Nardinocchi L., Puca R., Stanga S., Uberti D., Memo M., Govoni S., D'Orazi G., and, Racchi M., (2010) Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS ONE 5, e10171.
20. Lanni C., Racchi M., Memo M., Govoni S., and, Uberti D., (2012) p53 at the crossroads between cancer and neurodegeneration. Free Radic. Biol. Med. 52, 1727-1733.
21. Li T., Wen H., Brayton C., et al,. (2007) Moderate reduction of γ-secretase attenuates amyloid burden and limits mechanism-based liabilities. J. Neurosci. 27, 10849-10859.
22. Lu K. P., and, Zhou X. Z., (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signaling and disease. Nat. Rev. Mol. Cell Biol. 8, 904-916.
23. Mayeux R., Tang M. X., Jacobs D. M., Manly J., Bell K., Merchant C., Small S. A., Stern Y., Wisniewski H. M., and, Mehta P. D., (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46, 412-416.
24. Méplan C., Richard M. J., and, Hainaut P., (2000) Redox signalling and transition metals in the control of the p53 pathway. Biochem. Pharmacol. 59, 25-33.
25. Pangalos M. N., Jacobsen S. J., and, Reinhart P. H., (2005) Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem. Soc. Trans. 33, 553-558.
26. Puca R., Nardinocchi L., Gal H., et al,. (2008) Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. 68, 3707-3714.
27. Puca R., Nardinocchi L., Bossi G., Sacchi A., Rechavi G., Givol D., and, D'Orazi G., (2009) Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp. Cell Res. 315, 67-75.
28. Sadot E., Geiger B., Oren M., and, Ben-Ze'ev A., (2001) Down-regulation of beta-catenin by activated p53. Mol. Cell. Biol. 21, 6768-6781.
29. Terai K., Iwai A., Kawabata S., Tasaki Y., Watanabe T., Miyata K., and, Yamaguchi T., (2001) Amyloid-deposits in transgenic mice expressing human β amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 104, 299-310.
30. Uberti D., Carsana T., Bernardi E., Rodella L., Grigolato P., Lanni C., Racchi M., Govoni S., and, Memo M., (2002) Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J. Cell Sci. 115, 3131-3138.
31. Uberti D., Lanni C., Carsana T., Francisconi S., Missale C., Racchi M., Govoni S., and, Memo M., (2006) Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol. Aging 27, 1193-1201.
32. Uberti D., Cenini G., Olivari L., et al,. (2007) Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J. Neurochem. 103, 322-333.
33. Verdile G., Fuller S., Atwood C. S., Laws S. M., Gandy S. E., and, Martins R. N., (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol. Res. 50, 397-409.
34. Vousden K. H., and, Prives C., (2005) P53 and prognosis: new insights and further complexity. Cell 120, 7-10.
35. Walsh D. M., and, Selkoe D. J., (2007) Aβ Oligomers-a decade of discovery. J. Neurochem. 101, 1172-1184.
36. Wang Y., and, Gilmore T. D., (2001) LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim. Biophys. Acta 1538, 260-272.
37. Wang Y., and, Gilmore T. D., (2003) Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim. Biophys. Acta 1593, 115-120.
38. Wang S., Konorev E. A., Kotamraju S., Joseph J., Kalivendi S., and, Kalyanaraman B., (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 279, 25535-25543.
39. Yang Y., Geldmacher D. S., and, Herrup K., (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J. Neurosci. 21, 2661-2668.
40. Zhou X., and, Jia J., (2010) P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neurosci. Lett. 468, 320-325.